We are delighted to share with you all that Neurvati Neurosciences/GRIN Therapeutics, Inc. issued a press release today announcing that the first patient has been dosed in its global Phase 3 Beeline clinical trial of investigational radiprodil in GRIN-related neurodevelopmental disorder (GRIN-NDD).
You can find the press release here: https://lnkd.in/dvpctCTp
We also share a heartfelt letter of GRIN Therapeutics’ Chief Medical Officer, Michael Panzara, MD, MPH in which he announces this important milestone within our GRIN Community.
If you have any questions regarding this press release, please have a look at the FAQ’s on the GRIN Therapeutics website through the following link: https://lnkd.in/dCTemUpq